On September 4, 2026, a clinical trial update was recorded for the study titled "Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia." The trial, registered as NCT04447911, is listed as a Phase 4 study.
According to the registry, the current status of this trial is recruiting. The study is examining empagliflozin, an SGLT2 inhibitor, in patients with two specific types of hyponatremia: euvolemic and hypervolemic. Hyponatremia is a condition related to sodium regulation in the body, an area where vasopressin activity is physiologically relevant.
No results have been posted for this trial as of the listed date. The update reflects only the trial's registration status and design as recorded in the public database, not any outcomes or findings. Readers should not interpret a recruiting status as an indication of safety, efficacy, or eventual results.
This entry serves as a status update based solely on the publicly available trial record. Additional details about phase progression, enrollment, or outcomes would require further updates from the trial sponsor or registry.
For more background on vasopressin and its role in fluid and sodium balance, readers can consult the compound overview.